OCT 03, 2018 07:24 PM PDT

Single Cell Modified in CAR T Therapy Causes Deadly Relapse

WRITTEN BY: Carmen Leitch

One cell meant a very different outcome for a patient that was the recipient of a cutting-edge cancer therapy.  The process involves extracting a patient's immune cells, and genetically modifying them using a chimeric antigen receptor (CAR) lentivirus; it turns them into cancer killers. Those immune cells are then put back into the patients, where they go to work. However, a single cancer cell also got modified in this case. It went on to multiply billions of times, causing relapse and eventually killing the patient. The findings have been reported in Nature Medicine.

“In this case, we found that 100 percent of relapsed leukemic cells carried the CAR that we use to genetically modify T cells,” said the study’s lead author Marco Ruella, MD, an assistant professor of Hematology-Oncology at Penn Medicine. “This is the first time in hundreds of patients treated at Penn and other institutions that we’ve observed this mechanism of relapse, and it provides important evidence that steps in the delicate and complex process of engineering personalized cells can play a role in patient outcomes.”

The patient was part of a clinical trial at Penn; the aim was to treat an aggressive case of pediatric B-cell acute lymphoblastic leukemia (ALL) that had already relapsed three times. The patient's cancer went into total remission for nine months before it returned.

The therapy (described in the video) was created by scientists at Penn's Perelman School of Medicine and at Children’s Hospital of Philadelphia (CHOP). It utilizes T cells that are harvested from the patient. They are then treated with a CAR lentivirus, which trains them to find cells that express a protein called CD19. It will then attack those cells. Leukemia cells without CD19 are unaffected by this therapy.

In this case, the CAR lentivirus seems to have also gotten into a leukemia cell and enabled it to evade the immune cells. In the majority of ALL relapses, cancer cells don’t express CD19. There wasn’t any CD19 found in this patient’s cancer cells either. However, the cells tested positive for CAR. It was expressing a product that bound the CD19 antigen, so the trained immune cells could not recognize it.

Interestingly, the opposite case happened earlier this year. A single CAR T cell was able to divide enough times that it destroyed chronic lymphocytic leukemia (CLL).

“We learn so much from each patient, in both success or failure of this new therapy, that helps us improve these still-developing treatments so they can benefit more patients,” noted the senior author of this work, J. Joseph Melenhorst, PhD, an associate professor of Pathology and Laboratory Medicine and a member of Penn’s Center for Cellular Immunotherapies.

“This is a single case, but is still incredibly important and can help us refine the intricate processes required for manufacturing CAR-T cell therapy to ensure the best chance of long-term remissions,” he added.


Sources: Penn Medicine, Nature Medicine

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 03, 2018
Microbiology
NOV 03, 2018
Potential new Tuberculosis Treatment Found in Dirt
The pathogen that causes TB has been able to evolve, and often, the typical therapeutic for the illness does not work....
NOV 12, 2018
Neuroscience
NOV 12, 2018
Neuronal Connectivity Beyond The Hebb's Rule
New study finds evidence that neurons the fire together need not be connected to together electrically...
NOV 18, 2018
Neuroscience
NOV 18, 2018
How does the brain know when we are full?
Feeling full or satiation is conveyed to the brain by the gut hormones via the enteric neuronal afferents and the endocrine feedback pathways....
NOV 19, 2018
Neuroscience
NOV 19, 2018
Researchers identify neural pathways that control behavioral responses to noxious stimuli
Behavioral responses to the pain perception could range from reflexive withdrawal to more complex behaviors to avoid or decrease the pain. Neurons in the lateral division of the parabrachial...
DEC 06, 2018
Microbiology
DEC 06, 2018
A Bacterial Protein can Encourage Cancer Development
It's been suggested that a fifth of all cancers are caused by microbial infections, and new work indicates that the estimate is probably low....
DEC 10, 2018
Microbiology
DEC 10, 2018
The 'Deep Biosphere' of the Earth Teems with Life
Deep within the surface of the earth lies a gargantuan amount of carbon in the form of various types of microbial life....
Loading Comments...